Related Experiment Video
Updated: Feb 11, 2026

Isolation and Transplantation of Hematopoietic Stem Cells HSCs
Published on: February 25, 2007
Secondary Prophylaxis With Bioequivalent Generic Letermovir in Haploidentical Hematopoietic Stem Cell
Abhijit Baheti1, Suyash Bharat2
1Hematology, Deenanath Mangeshkar Hospital, Pune, IND.
Abstract:
Cytomegalovirus (CMV) reactivation poses a significant risk post-allogeneic hematopoietic stem cell transplantation (HSCT), particularly in high-risk settings. This report details the clinical course of a relapsed acute myeloid leukemia patient who underwent haploidentical HSCT following graft failure linked to CMV viremia. Letermovir prophylaxis effectively suppressed CMV but was discontinued on day +60, following which the patient experienced transient reactivation. The episode was successfully managed in the outpatient setting with oral valganciclovir. This case highlights the importance of sustained CMV prophylaxis and the role of accessible antiviral strategies in optimizing transplant outcomes.
Related Concept Videos
Multipotency of Hematopoietic Stem Cells
Regulation of Hematopoietic Stem Cells
Bioequivalence: Overview
Induced Pluripotent Stem Cells
Primary and Secondary Growth in Roots and Shoots
Secondary Active Transport

